Faron, etusivu

releases and publications

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Regulatory

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Regulatory

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Regulatory

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Faron Pharmaceuticals Ltd: Grant of Options

Insider Transaction Regulatory
Next
Back to top